Location:Home /  Resource
Past list
COVID-19 Webinar Series: The use of MGI sequencing platform in a translational response against COVID-19
Release date:2021-05-21Writer:MGIViews:508Share
The dynamics underlying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection remain poorly understood. We identified a small cluster of individuals with two episodes of 2019 coronavirus disease (COVID-19) in March and late May of 2020. In the first episode, individuals presented an enhanced innate response compared to healthy individuals, but neutralizing humoral immunity was not fully achieved. The second episode was associated with different SARS-CoV-2 strains, higher viral loads, and clinical symptoms. The identification that some individuals with mild COVID-19 may have controlled SARS-CoV-2 replication without developing detectable humoral immunity raises the possibility that re-infection is more frequent than supposed, but weakly documented.
Dr. Thiago Moreno L. Souza

National Institute of Science and Technology for Innovation on Neglected Population Diseases (INCT-IDPN), and Oswaldo Cruz Institute, Immunopharmacology Laboratory, Rio de Janeiro, RJ, Brazil

If you have any questions, you can send an email to:
MGI-service@mgi-tech.com
Quick Contact